Parion Sciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Parion Sciences sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Parion Sciences: 9 sponsored US clinical trials, none currently recruiting.

Parion Sciences sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Xerostomia, with 1 trials.

Top-decile sponsor footprint

Parion Sciences ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 2

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

NCT02871778
TERMINATED Phase 2

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02831387
TERMINATED Phase 2

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02824913
COMPLETED Phase 2

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109
COMPLETED Phase 2

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

NCT02343445
COMPLETED Phase 1

Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT02242032
COMPLETED Phase 1

An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

NCT01369589
COMPLETED Phase 2

A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome

NCT00852839
COMPLETED Phase 1

Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

NCT00274313

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6

Therapeutic Areas

Xerostomia 1
Cystic Fibrosis 1
Sjogren's Syndrome 1

How the Parion Sciences early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Xerostomia (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Parion Sciences: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Parion Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Parion Sciences4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Parion Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Parion Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Parion Sciences page

9 registered trials is a research-attention snapshot, not an endorsement of Parion Sciences or any single study.

  • None of Parion Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Xerostomia is the condition Parion Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Xerostomia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Parion Sciences pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.